Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 10;8(4):357-376.
doi: 10.1007/s13167-017-0117-3. eCollection 2017 Dec.

Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice

Affiliations

Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice

Rostyslav V Bubnov et al. EPMA J. .

Abstract

Background: Microbiome-modulating interventions are promising for treatment and prevention of metabolic syndrome. The number of probiotic strains demonstrated ability to decrease cholesterol level in vivo, however, it was poorly confirmed in a clinical setting. The aim was to study the effects of L. acidophilus IMV B-7279, L. casei IMV B-7280, B. animalіs VKL and B. animalіs VKB separately and in various compositions on the level of serum cholesterol, gut microbiota contents and liver morphology on a high-calorie-induced obesity model in BALB/c mice.

Materials and methods: We used for the study female BALB/c mice 6-8 weeks old (18-24 g). Experimental animals were fed by a fat-enriched diet (FED), and 8 experimental groups were formed (12 mice in each group) to test strains of probiotic bacteria L. delbrueckii subsp. bulgaricus IMV B-7281, L. casei IMV B-7280, B. animalіs VKL and B. animalіs VKB and compositions. We used ultrasound for in vivo assessment of the liver and visceral (mesenteric) fat size. In the blood serum of the obese mice, the level of cholesterol was estimated. The liver morphology and gut microbiota of obese mice were studied.

Results: We revealed that after treatment with all of the studied probiotic bacteria and compositions of B. animalis VKL/B. animalis VKB/L. casei IMV B-7280, the weight of obese mice decreased, and cholesterol and its fraction levels in serum were reduced. The size of the liver slightly decreased after treatment with L. delbrueckii subsp. bulgaricus IMV B-7281, B. аnimalis VKB or probiotic compositions; we observed reduction of the mesenteric fat size after injection of all these probiotic bacteria (separately) and probiotic compositions. We defined the strain-dependent effects on serum lipid profiles, liver morphology and the gut microbiota. The B. animalis VKL/B. animalis VKB/L. casei IMV B-7280 composition effectively recovered the liver morphological structure of obese mice. The number of Lactobacillus spp., Bifidobacterium spp. and coliform bacteria increased, the number of staphylococci and streptococci reduced, and the number of microscopic fungi significantly decreased in the gut of obese mice after treatment with L. casei IMV B-7280, L. delbrueckii subsp. bulgaricus IMV B-7281, B. animalis (separately) or their compositions.

Conclusion: L. casei IMV B-7280 (separately) and a composition of B. animalis VKL/B. animalis VKB/L. casei IMV B-7280 are effective at decreasing the weight of obese mice, decreasing cholesterol level, restoring the liver morphology and beneficially modulating the gut microbiome in high-calorie-induced obesity.

Keywords: Bifidobacterium; Cholesterol; Gut microbiota; Lactobacillus; Liver; Metabolic syndrome; Mouse model: mesenteric fat; Obesity; Predictive preventive personalized medicine; Ultrasound.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Competing interests

Authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Ultrasound examination of mice along the experiment; (A) obese mouse (general view); (B) cross-section abdominal scan (transverse organo-complex record); (C) organs evaluation on US, L liver, K kidney
Fig. 2
Fig. 2
Ultrasound examination (A) to obtain longitudinal scans of the abdominal cavity of mice along the experiment (sagittal organo-complex records); B measurement of visceral (mesenteric) fat
Fig. 3
Fig. 3
Ultrasound examination of the liver (A) during the experiment; (B) the enlarged liver of obese mouse; (C) liver size decreasing after treatment
Fig. 4
Fig. 4
Cholesterol levels; (A) the concentration of total, free and ester cholesterol in the blood serum of BALB/c line mice that received FED; (B) changes of total cholesterol levels in the blood serum during the experiment in all groups
Fig. 5
Fig. 5
Liver tissue of intact (A, B) and obese (C, D) mice. (A, B) structure of liver tissue is preserved as normal, pathologic changes not detected. (C, D) fatty degeneration/necrosis of hepatocytes (A – x200 magnification, B – x400 magnification)
Fig. 6
Fig. 6
Liver tissue of mice that received FED and L. casei IMV B-7280 (A), B. animalіs VKL (B), B. animalis VKL/B. animalis VKB/L. casei IMV B-7280 (C), B. animalis VKB (D, E), L. delbrueckii subsp. bulgaricus IMV B-7281 (F), B. animalis VKB/B. animalis VKL composition (G). (A) restoring liver structure, lipid inclusions are detected in hepatocytes. Partial necrosis and fatty degeneration of hepatocytes (x400 magnification). (B) restoring structure, lipid inclusions in hepatocytes and existing isolated sites with lymphocytes and macrophages infiltrates are detected; partial necrosis and fatty degeneration of hepatocytes (×400 magnification). (C) restoring structure, degenerative changes not detected. Partial necrosis of hepatocytes (x400 magnifications). (D, E) partial necrosis and fatty degeneration of hepatocytes (D – ×1000 magnification, E – ×400 magnification). (F) necrosis and fatty degeneration of hepatocytes (×400 magnification). (G) necrosis and fatty degeneration of hepatocytes (×400 magnification)

Similar articles

Cited by

References

    1. WHO: Obesity and overweight: Fact sheet N. 311. http://www.who.int/mediacentre/factsheets/fs311/en/ Accessed 19 July 2017.
    1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010;375(9710):181–3. 10.1016/S0140-6736(09)61794-3. - PubMed
    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1–6. doi: 10.1097/01.hco.0000200416.65370.a0. - DOI - PubMed
    1. Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the west Virginian population. Int J Med Sci. 2016;13(1):25–38. 10.7150/ijms.13800. - PMC - PubMed
    1. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–455. doi: 10.1016/S0002-9343(99)00271-5. - DOI - PubMed

LinkOut - more resources